DelveInsight’s “Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Prostate Cancer, historical and forecasted epidemiology as well as the Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Prostate Cancer, offering comprehensive insights into the Prostate Cancer revenue trends, prevalence, and treatment landscape. The report delves into key Prostate Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Prostate Cancer therapies. Additionally, we cover the landscape of Prostate Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Prostate Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Prostate Cancer space.

To Know in detail about the Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prostate Cancer Market Forecast

Some of the key facts of the Prostate Cancer Market Report: 

• The Prostate Cancer market size was valued ~USD 7,000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In October 2024, A study showed that Johnson & Johnson’s Erleada outperformed Astellas and Pfizer’s Xtandi in real-world treatment of metastatic castration-sensitive prostate cancer (mCSPC). While Xtandi previously led the market, analysis of more than 3,700 patients found Erleada reduced the risk of death by 23% over Xtandi after 24 months. At that point, 88% of patients on Erleada remained alive, aligning with findings from the Phase 3 TITAN trial, compared to an 85% survival rate for Xtandi.

• In September 2024, Ipsen reported that the Phase III CONTACT-02 trial evaluating Cabometyx® and atezolizumab for metastatic castration-resistant prostate cancer (mCRPC) showed a modest improvement in overall survival, though it was not statistically significant, while achieving its progression-free survival (PFS) endpoint.

• In September 2024, Foundation Medicine has obtained FDA approval for its FoundationOne®CDx and Liquid CDx as companion diagnostic tools for identifying BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) patients eligible for treatment with Lynparza®.

• In July 2024, The ARANOTE trial demonstrated that NUBEQA® combined with ADT significantly enhanced radiological progression-free survival (PFS) in patients with metastatic hormone-sensitive, castration-resistant prostate cancer (mHSPC).

• In July 2024, The FDA has awarded fast-track designation to SYNC-T SV-102 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

• In 2023, the United States accounted for the largest market share for metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) within the 7MM, at 63% and 61%, respectively, with the EU4 and the UK following.

• The current U.S. market for metastatic castration-resistant prostate cancer (mCRPC) includes therapies such as JEVTANA, ZYTIGA, XTANDI, XOFIGO, among others. In 2023, XTANDI held the largest market share, reaching approximately USD 2,800 million.

• Key Prostate Cancer Companies: Bayer, Johnson & Johnson Innovative Medicine (Janssen), Astellas Pharma, Pfizer, Janssen Research & Development/Tesaro, Sanofi, MacroGenics, Candel Therapeutics, Kangpu Biopharmaceuticals, Point Biopharma, AstraZeneca, Essa Pharma, and others

• Key Prostate Cancer Therapies: NUBEQA (darolutamide), ERLEADA (apalutamide), XTANDI (enzalutamide), AKEEGA (niraparib + abiraterone acetate + prednisone), JEVTANA + prednisone, MGC018 (vobramitamab duocarmazine), CAN-2409, KPG-121, 177Lu-PNT2002 (PNT2002), Capivasertib, CAN-2409 + valacyclovir + radiation therapy ± ADT, MGC018, EPI-7386, and others

• The Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prostate Cancer pipeline products will significantly revolutionize the Prostate Cancer market dynamics.

• According to DelveInsight’s estimates, the total prevalent cases of prostate cancer in the 7MM reached approximately 8,241,400 in 2023; however, this number does not represent the treatable population. These cases are expected to grow over the forecast period from 2024 to 2034.

• In 2023, the United States reported the highest prevalence of prostate cancer cases, with around 3,803,500 cases.

• According to estimates, in 2023, the majority of prostate cancer cases in the US were diagnosed in individuals aged 65 to 74, representing nearly 40% of all cases.

• In the US, the total diagnosed prevalent cases of prostate cancer in 2023 were highest in the locally advanced stages (Stage I–III), with more than 903,700 cases. This was followed by cases of biochemical recurrence/progression and metastatic cases.

Prostate Cancer Overview

Prostate cancer is a form of cancer that develops in the prostate, a small gland in men that produces seminal fluid, which nourishes and transports sperm. It typically grows slowly and may initially remain confined to the prostate, where it may not cause serious harm. However, certain types of prostate cancer can be aggressive and spread to other areas of the body, including bones and lymph nodes. Symptoms often include difficulty urinating, pelvic discomfort, and, in advanced cases, bone pain. Early detection through screenings, such as prostate-specific antigen (PSA) tests, can improve treatment outcomes.

Get a Free sample for the Prostate Cancer Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/prostate-cancer-market-insight

Prostate Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Prostate Cancer Epidemiology Segmentation:

The Prostate Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Prostate Cancer

• Prevalent Cases of Prostate Cancer by severity

• Gender-specific Prevalence of Prostate Cancer

• Diagnosed Cases of Episodic and Chronic Prostate Cancer

Download the report to understand which factors are driving Prostate Cancer epidemiology trends @ Prostate Cancer Epidemiology Forecast

Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prostate Cancer market or expected to get launched during the study period. The analysis covers Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.  Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Prostate Cancer Pipeline Development Activities.

It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Prostate Cancer Therapies and Key Companies

• NUBEQA (darolutamide): Bayer

• ERLEADA (apalutamide): Johnson & Johnson Innovative Medicine (Janssen)

• XTANDI (enzalutamide): Astellas Pharma/Pfizer

• AKEEGA (niraparib + abiraterone acetate + prednisone): Janssen Research & Development/Tesaro

• JEVTANA + prednisone: Sanofi

• MGC018 (vobramitamab duocarmazine): MacroGenics

• CAN-2409: Candel Therapeutics

• KPG-121: Kangpu Biopharmaceuticals

• 177Lu-PNT2002 (PNT2002): Point Biopharma

• Capivasertib: AstraZeneca

• CAN-2409 + valacyclovir + radiation therapy ± ADT: Candel Therapeutics

• MGC018: MacroGenics

• EPI-7386: Essa Pharma

Discover more about therapies set to grab major Prostate Cancer market share @ Prostate Cancer Treatment Landscape

Prostate Cancer Market Drivers

• Rising Incidence Rates

• Advancements in Treatment Options

• Increased Awareness and Screening

• Government Initiatives

• Innovative Diagnostic Techniques

Prostate Cancer Market Barriers

• High Treatment Costs

• Regulatory Challenges

• Limited Awareness in Certain Populations

• Adverse Effects of Treatments

• Competition from Alternative Therapies

Scope of the Prostate Cancer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Prostate Cancer Companies: Bayer, Johnson & Johnson Innovative Medicine (Janssen), Astellas Pharma, Pfizer, Janssen Research & Development/Tesaro, Sanofi, MacroGenics, Candel Therapeutics, Kangpu Biopharmaceuticals, Point Biopharma, AstraZeneca, Essa Pharma, and others

• Key Prostate Cancer Therapies: NUBEQA (darolutamide), ERLEADA (apalutamide), XTANDI (enzalutamide), AKEEGA (niraparib + abiraterone acetate + prednisone), JEVTANA + prednisone, MGC018 (vobramitamab duocarmazine), CAN-2409, KPG-121, 177Lu-PNT2002 (PNT2002), Capivasertib, CAN-2409 + valacyclovir + radiation therapy ± ADT, MGC018, EPI-7386, and others

• Prostate Cancer Therapeutic Assessment: Prostate Cancer current marketed and Prostate Cancer emerging therapies

• Prostate Cancer Market Dynamics: Prostate Cancer market drivers and Prostate Cancer market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Prostate Cancer Market Access and Reimbursement 

To know more about Prostate Cancer companies working in the treatment market, visit @ Prostate Cancer Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Prostate Cancer Market Report Introduction

2. Executive Summary for Prostate Cancer

3. SWOT analysis of Prostate Cancer

4. Prostate Cancer Patient Share (%) Overview at a Glance

5. Prostate Cancer Market Overview at a Glance

6. Prostate Cancer Disease Background and Overview

7. Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Prostate Cancer 

9. Prostate Cancer Current Treatment and Medical Practices

10. Prostate Cancer Unmet Needs

11. Prostate Cancer Emerging Therapies

12. Prostate Cancer Market Outlook

13. Country-Wise Prostate Cancer Market Analysis (2020–2034)

14. Prostate Cancer Market Access and Reimbursement of Therapies

15. Prostate Cancer Market Drivers

16. Prostate Cancer Market Barriers

17.  Prostate Cancer Appendix

18. Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/